Biotrial

Executive Summary

Biotrial is a full-service contract research organization (CRO) headquartered in Rennes, France, founded in 1989. It specializes in supporting biotech and pharma companies from preclinical through clinical development. The company currently manages a portfolio of Phase 1 and Phase 1/2 trials, including studies for LPH-5 (safety/tolerance), SQY51 (Duchenne Muscular Dystrophy), and others. As a private CRO, Biotrial generates revenue by providing research services rather than developing proprietary drugs. Its business model is relatively stable, with growth driven by new client contracts and successful trial execution. Recent completed studies (ITF2357, VNA-318) demonstrate operational capability, while the ongoing LPH-5 recruitment indicates continued demand. The company's conviction score is moderate, reflecting its role as a service provider with predictable but limited upside compared to drug developers.

Upcoming Catalysts (preview)

• Q2 2026LPH-5 Phase 1 Safety/Tolerance Trial Completion and Data Readout85% success
• TBDNew Contract Wins with Biotech/Pharma Clients70% success
• TBDPotential Expansion of Service Offerings or Geographic Reach50% success